TERT基因rs2853669和rs10069690多态性与仑伐替尼治疗晚期肝癌近期疗效的相关性  

Association of TERT rs2853669 and rs10069690 polymorphisms with lenvatinib short-term efficacy and safety in advanced hepatocelluer Carcinoma

作　　者：唐文军 张诚胜 罗靖茹 林舒 闫其星 TANG Wenjun;ZHANG Chengsheng;LUO Jingru;LIN Shu;YAN Qixing(Department of Oncology,The Second Affiliated Hospital of Hainan Medical College,Haikou 570311,China;Department of Pharmacy,The Second Affiliated Hospital of Hainan Medical College,Haikou 570311,China)

机构地区：[1]海南医学院第二附属医院肿瘤内科,海南海口570311 [2]海南医学院第二附属医院药学部,海南海口570311

出　　处：《西部医学》2025年第4期527-531,共5页Medical Journal of West China

基　　金：海南省自然科学基金面上项目(822MS180);海南省卫计委科研项目(19A200117)。

摘　　要：目的探讨晚期原发性肝细胞癌(HCC)患者TERT基因rs2853669和rs10069690的多态性与仑伐替尼的近期疗效及不良反应的相关性。方法从TCGA数据库中获取HCC的基因表达数据及临床资料,运用R语言分析TERT基因的表达差异及其与预后的相关性。选取2018年12月—2022年8月在我院经病理确诊、一线接受仑伐替尼治疗并具有完整资料的晚期HCC患者124例。采集3 mL外周静脉血,高通量测序鉴定rs2853669和rs10069690的基因型,分析其与仑伐替尼治疗晚期HCC的近期疗效及不良反应的相关性。结果有106例患者可评估疗效,其中部分缓解(PR)44例(41.5%),疾病稳定(SD)与疾病进展(PD)62例(58.5%)。rs10069690的等位基因分布频次在两组间比较差异有统计学意义(P=0.024),携带T等位基因的患者的PR率显著高于携带C等位基因的患者(OR=2.250,95%CI:1.103~4.591)。不良反应中高血压、手足综合征、腹泻、蛋白尿、食欲下降及疲乏的比例分别为29.2%、20.8%、19.8%、21.7%、39.6%、44.3%。rs2853669和rs10069690的基因型与不良反应的发生率无相关性(P>0.05)。结论携带TERT rs10069690 T等位基因的晚期HCC患者给予仑伐替尼治疗可能具有较好的近期疗效。Objective To evaluate the association of TERT gene polymorphisms with short-term efficacy and safety of lenvatinib in advanced hepatocelluer carcinoma.Methods The gene expression data and clinical data of hepatocelluer carcinoma were downloaded from the TCGA database.R software package was used to analyze the difference of TERT expression and its correlation with patient’s prognosis.A total of 124 cases with pathologically confirmed at the Affiliated Hospital from December 2018 to August 2022 were collected which received lenvatinib and all of them with complete data.3 mL of peripheral venous blood sample was obtained from each patient before therapy,then single nucleotide polymorphism of rs10069690 and rs2853669 was conducted using high throughout sequencing technology,the relationship among the genotypes with therapeutic short-term efficacy and safety was analyzed.Results 106 patients could be evaluated for curative effect,among which 44 patients were PR and 62 patients were SD/PD.The most common any-grade adverse events were hypertension,hand-foot syndrome,diarrhoea,proteinuria,decreased appetite,fatigue and the incidence were 29.2%,20.8%,19.8%,21.7%,39.6%,44.3%respectively.The polymorphism of rs10069690 were related with the therapeutic response(P=0.024),compared with C allele,individuals with T allele had a higher therapeutic response(OR=2.250,95%CI:1.103~4.591).The polymorphisms of rs10069690 and rs2853669 were not statistically related with the adverse reactions.Conclusion Patients with hepatocelluer carcinoma who carries the rs10069690 T allele have better efficacy when treated with lenvatinib.

关 键 词：TERT基因 仑伐替尼 肝癌 近期疗效 

分 类 号：R735.7[医药卫生—肿瘤]